Navigation Links
Amira Pharmaceuticals and GlaxoSmithKline Enter Global Agreement for FLAP Inhibitor Program
Date:2/4/2008

Deal follows positive phase I data from novel product candidate AM103 for

the oral treatment of respiratory disease

SAN DIEGO, Feb. 4 /PRNewswire/ -- Amira Pharmaceuticals and GlaxoSmithKline today announced they have entered into a worldwide exclusive agreement to develop, manufacture and commercialize FLAP (5-Lipoxygenase Activating Protein ) inhibitors for the treatment of respiratory and cardiovascular disease.

Under the terms of the agreement GSK will be granted an exclusive, worldwide license to develop, manufacture and commercialize Amira's FLAP inhibitors, including AM103 and other compounds within the current development program. In the event that all potential development and regulatory milestones are successfully achieved, Amira could receive up to US $425 million in upfront and milestone payments. In addition, Amira will be entitled to receive tiered royalty payments based on worldwide net sales and commercial sales milestones.

Initial development activities will focus on candidate compound AM103, for the treatment of asthma. Positive data, from a phase I study completed in November 2007, show AM103 has the potential as a once-daily, oral, non-steroidal asthma treatment. In this study the compound was also well-tolerated.

Peppi Prasit, Chief Scientific Officer and Co-Founder Amira said: "To have identified such a positive drug candidate and progressed to the completion of phase I clinical trials just two years after the company was founded is a tremendous achievement for the team at Amira. We are delighted that GlaxoSmithKline will be taking this asset into full development. With their experience and expertise in this area we hope that AM103 will become the first FLAP inhibitor available to patients worldwide to treat symptoms of asthma and possibly other inflammatory diseases."

"This is a momentous day in the young life of Amira," said Bob Baltera, Chief Executive Officer, Amira. "This deal valid
'/>"/>

SOURCE Amira Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Amira Pharmaceuticals Appoints First Vice President of Development
2. Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease
3. Poniard Pharmaceuticals Announces Upcoming Conference Participation
4. Webcast Alert: Oscient Pharmaceuticals Announces Date for Release of Fourth Quarter Financial Results
5. Jazz Pharmaceuticals, Inc. Announces Submission of Complete Response to FDA Approvable Letter for LUVOX(R) CR
6. Acura Pharmaceuticals, Inc. Announces Approval to List Shares on NASDAQ and Effective Feb. 4, 2008 a New Trading Symbol: ACUR
7. Tigris Pharmaceuticals Appoints Pedro Granadillo to Board of Directors
8. Tibotec Pharmaceuticals a Respectful Partner to HIV Community in Pricing of Novel New HIV NNRTI, INTELENCE
9. Arena Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
10. MAP Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
11. Transcept Pharmaceuticals to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2014)... News) -- The holidays can be a challenge for ... trigger major meltdowns, an expert says. "Holidays with ... but when you have children with special needs, some ... professor at University of the Sciences in Philadelphia, said ... let your hosts or visitors know what special requirements ...
(Date:11/23/2014)... To show thanks to new and old customers, iFitDress.com ... dresses for weddings. Customers who need custom outfits can ... distinguished dress manufacturer, and it is among the ones which ... very long time. The CEO of this company says, "iFitDress.com ... to buy not only a beautiful dress, but also a ...
(Date:11/23/2014)... AngelWeddingDress.com has recently updated ... of beach wedding dresses. “If you are looking for ... as soon as possible. Here you can enjoy 70% ... says. , Holding a big marriage ceremony is the ... beautiful beach wedding dress is uppermost priority. Ophelia, one ...
(Date:11/23/2014)... 2014 The FDA is Watching: , ... On-Demand Webinar**, Dec. 11, 2014 ? Any Time at ... focus on promotional activities is no longer limited to ... looking at websites, Twitter, journal articles, TV appearances, Facebook ... Dec. 11, for On-Demand access to Timothy Ayers and ...
(Date:11/23/2014)... November 23, 2014 BambooFlooringChina.com , the ... click strand woven bamboo flooring collection. Now, the ... to the company’s CEO, the promotion is valid until Dec. ... comes with a smooth and dust-free surface, which makes it ... in the industry, the company wants to make its website ...
Breaking Medicine News(10 mins):Health News:Holidays Can Be Sensory Overload for Kids With Autism 2Health News:iFitDress.com: Wonderful White Evening Dresses Now Available 2Health News:Beach Wedding Dresses Added to Outstanding Online Dress Company AngelWeddingDress.com 2Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 2Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 3Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 4Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 5Health News:Click Strand Woven Bamboo Flooring From Famous Bamboo Flooring Company BambooFlooringChina.com 2
... By Kathleen Doheny HealthDay Reporter , FRIDAY, ... overweight or obese tend to befriend and date people ... The finding echoes previous research that found health ... study author Dr. Tricia M. Leahey, an assistant professor ...
... , FRIDAY, Jan. 14 (HealthDay News) -- Riding in a convertible ... warns. U.S. researchers conducted sound level measurements using five different ... noise levels were above 85 decibels (dB) when the top was ... (mph) or faster. Exposure to noise levels above 85 dB ...
... News) -- Among older adults who,ve recently had a ... to take medications meant to prevent another heart attack, ... Harvard Medical School researchers and colleagues analyzed the pharmacy ... who recently had a heart attack and were prescribed ...
... By Jenifer Goodwin HealthDay Reporter , FRIDAY, Jan. ... in love? Ever feel like the passing years, the never-ending ... have quashed your infatuation for your spouse? New ... to that passion and romance for decades or more. ...
... Amanda Gardner HealthDay Reporter , THURSDAY, Jan. ... that they will lower the maximum amount of the ... as Vicodin and Percocet because of reports of severe ... the upper threshold of acetaminophen in prescription drugs containing ...
... E. coli uses a laser to detect and monitor ... The technique described this month in the International Journal ... incidence of waterborne disease outbreaks. Microbial contamination of water ... are the leading causes of illness and death in the ...
Cached Medicine News:Health News:Overweight Young Adults Often Have Overweight Friends, Sweethearts 2Health News:Overweight Young Adults Often Have Overweight Friends, Sweethearts 3Health News:Riding With the Top Down May Put Hearing at Risk 2Health News:Heart Attack Patients With Kidney Problems Often Skip Meds 2Health News:Brain Scans Show Married Love Can Last 2Health News:Brain Scans Show Married Love Can Last 3Health News:FDA Lowers Amount of Acetaminophen Allowed in Prescription Painkillers 2Health News:FDA Lowers Amount of Acetaminophen Allowed in Prescription Painkillers 3Health News:Speeding up E. coli detection 2
(Date:11/21/2014)...  Heated dialogue in recent months about the rising ... to Gilead,s new hepatitis C drug Harvoni® – has ... what it means to put a price on patient ... while drug pricing is one of the most debated ... general business and ethical standpoint – it is also ...
(Date:11/21/2014)... , 21. November 2014 ... heute bekannt gegeben, dass die Europäische ... die Kennzeichnung als Orphan-Medizinprodukt an Palovarotene ... Unternehmens zur Behandlung von Fibrodysplasia ossificans ... stark beeinträchtigende genetische Krankheit, die von ...
(Date:11/21/2014)... 20, 2014  Edwards Lifesciences Corporation (NYSE: ... heart valves and hemodynamic monitoring, announced today that it ... support a strong launch of Edwards Lifesciences Foundation,s new ... improve the global communities where its employees live and ... giving will exceed $8 million, including more than $7 ...
Breaking Medicine Technology:"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 2"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 3"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 4"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 5Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 2Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 3Edwards Lifesciences Increases Charitable Giving In 2014 To Support Launch Of Every Heartbeat Matters 2
The K-ASSAY Rheumatoid Factor Control Set is intended to be used as a consistent test sample of known concentration for monitoring the performance of K-ASSAY immunoturbidimetric assay for quantifying...
... Urine Controls are supplied as ... requiring no reconstitution or dilution. ... urine, fortified to target levels ... Preservatives including sodium azide have ...
... Liquid Lipid Control is intended for use ... test sample of known concentration for monitoring ... K-ASSAY Liquid Lipid Control with patient serum ... listed constituents. The user can compare observations ...
The K-ASSAY ITA Lyophilized Multi-Control Set is intended to be used as a consistent test sample of known concentration for monitoring the performance of K-ASSAY immunoturbidimetric assays for the li...
Medicine Products: